Nasreen C Jahed
Overview
Explore the profile of Nasreen C Jahed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
764
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malarkey M, Fu A, Mannan N, Shaw O, Haight T, Cota M, et al.
JAMA Netw Open
. 2024 Jul;
7(7):e2420090.
PMID: 38980675
Importance: Many military service members and veterans report insomnia after sustaining traumatic brain injury (TBI). Limitations of first-line treatment, cognitive-behavioral therapy for insomnia (CBT-I), include availability of qualified clinicians, low...
2.
Erlandson K, Kitch D, Tierney C, Sax P, Daar E, Tebas P, et al.
AIDS
. 2014 Jan;
27(13):2069-79.
PMID: 24384588
Objective: To compare the effect that initiating different antiretroviral therapy (ART) regimens has on weight, BMI, and lean body mass (LBM) and explore how changes in body composition are associated...
3.
McComsey G, Kitch D, Sax P, Tierney C, Jahed N, Melbourne K, et al.
J Acquir Immune Defic Syndr
. 2013 Oct;
65(2):167-74.
PMID: 24121755
Background: The association of inflammatory biomarkers with clinical events after antiretroviral therapy initiation is unclear. Methods: A5202 randomized 1857 treatment-naive subjects to abacavir/lamivudine or tenofovir-DF/emtricitabine with efavirenz or atazanavir/ritonavir. Substudy...
4.
McComsey G, Kitch D, Daar E, Tierney C, Jahed N, Melbourne K, et al.
AIDS
. 2012 May;
26(11):1371-85.
PMID: 22546988
Background: The effect of specific antiretrovirals on inflammation is unclear. Methods: A5224s was a substudy of A5202, which randomized HIV-infected treatment-naïve patients to blinded abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) with...
5.
Sax P, Tierney C, Collier A, Daar E, Mollan K, Budhathoki C, et al.
J Infect Dis
. 2011 Sep;
204(8):1191-201.
PMID: 21917892
Background: AIDS Clinical Trials Group A5202 compared blinded abacavir/lamivudine (ABC/3TC) to tenofovir DF/emtricitabine (TDF/FTC) with efavirenz (EFV) or atazanavir/ritonavir (ATV/r) in human immunodeficiency virus (HIV)-infected treatment-naive patients, stratified by screening...
6.
McComsey G, Kitch D, Sax P, Tebas P, Tierney C, Jahed N, et al.
Clin Infect Dis
. 2011 Jun;
53(2):185-96.
PMID: 21690627
Background: We compare the effect of 4 different antiretroviral regimens on limb and visceral fat. Methods: A5224s was a substudy of A5202, a trial of human immunodeficiency virus type 1...
7.
McComsey G, Kitch D, Daar E, Tierney C, Jahed N, Tebas P, et al.
J Infect Dis
. 2011 May;
203(12):1791-801.
PMID: 21606537
Background: Long-term effects of abacavir (ABC)-lamivudine (3TC), compared with tenofovir (TDF)-emtricitabine (FTC) with efavirenz (EFV) or atazanavir plus ritonavir (ATV/r), on bone mineral density (BMD) have not been analyzed. Methods:...
8.
Daar E, Tierney C, Fischl M, Sax P, Mollan K, Budhathoki C, et al.
Ann Intern Med
. 2011 Feb;
154(7):445-56.
PMID: 21320923
Background: Limited data compare once-daily options for initial therapy for HIV-1. Objective: To compare time to virologic failure; first grade-3 or -4 sign, symptom, or laboratory abnormality (safety); and change...
9.
Duke T, Jahed N, Veneroso C, Da Roza R, Johnson O, Hoffman D, et al.
Oncol Rep
. 2010 Sep;
24(5):1277-84.
PMID: 20878121
We investigated a cluster of three cases of inflammatory breast cancer (IBC) diagnosed within 10 months in an office setting of 24 people. Information about medical history, pregnancy history, family...
10.
Sax P, Tierney C, Collier A, Fischl M, Mollan K, Peeples L, et al.
N Engl J Med
. 2009 Dec;
361(23):2230-40.
PMID: 19952143
Background: The use of fixed-dose combination nucleoside reverse-transcriptase inhibitors (NRTIs) with a nonnucleoside reverse-transcriptase inhibitor or a ritonavir-boosted protease inhibitor is recommended as initial therapy in patients with human immunodeficiency...